M&A Corner
ERYTECH and PHERECYDES Announce Merger and Name Change to PHAXIAM Therapeutics03 Jul 2023
ERYTECH and PHERECYDES have merged and rebranded as PHAXIAM Therapeutics, a clinical-stage biopharmaceutical company focused on developing extended bacteriophage therapies... Continue Reading
|
Quest Diagnostics Completes Acquisition of Haystack Oncology27 Jun 2023
Quest Diagnostics has completed its acquisition of Haystack Oncology for $450M. The acquisition brings Haystack’s MRD testing technology for early... Continue Reading
|
Tourmaline Bio, Talaris Therapeutics Announce Reverse Merger in Stock Deal27 Jun 2023
Talaris Therapeutics and Tourmaline Bio have announced a reverse merger, forming a new company focused on developing an anti-IL 6... Continue Reading
|
Bio-Techne to Acquire Lunaphore27 Jun 2023
Bio-Techne Corporation has announced the acquisition of Lunaphore, a developer of automated spatial biology solutions for research and clinical applications.... Continue Reading
|
Solve Therapeutics, Inc. Acquires Cereius, Inc., a Duke University Spin-Out27 Jun 2023
Solve Therapeutics has acquired Cereius, a company focused on developing targeted radiodiagnostics and radiotherapeutics for cancer patients. The acquisition complements... Continue Reading
|
Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics.27 Jun 2023
Aeglea Biotherapeutics has completed the acquisition of Spyre Therapeutics, a biotechnology company focused on inflammatory bowel disease (IBD) treatments. Aeglea... Continue Reading
|
Thermo Fisher Scientific Completes Acquisition of MarqMetrix27 Jun 2023
Thermo Fisher Scientific has completed the acquisition of MarqMetrix, a developer of Raman-based spectroscopy solutions. The acquisition adds complementary in-line... Continue Reading
|
Quest Diagnostics Completes Acquisition of Haystack Oncology, Adding Sensitive MRD Liquid Biopsy Technology to Cancer Diagnostics Portfolio27 Jun 2023
Quest Diagnostics has finalized its acquisition of Haystack Oncology, a company specializing in minimal-residual disease testing using circulating tumor DNA.... Continue Reading
|
Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical27 Jun 2023
Telix Pharmaceuticals has announced the acquisition of Lightpoint Medical and its SENSEI radio-guided surgery business. The acquisition will strengthen Telix’s... Continue Reading
|
Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities27 Jun 2023
Simulations Plus has acquired Immunetrics, a modeling and simulation company focused on drug development in oncology, immunology, and autoimmune diseases.... Continue Reading
|